GSK and Roche announce collaboration

10-Dec-2001

GlaxoSmithKline plc and Roche have signed an agreement to co- develop and co-promote ibandronate, currently in Phase III clinical development, for the treatment and prevention of postmenopausal osteoporosis. Given the promising clinical trial results, Roche will be able to take full advantage of the potential of this exciting and promising medicine by collaborating with a strong development and marketing partner. Combining Roche and GSK's development, marketing and sales capabilities will provide the maximum added value for patients and prescribers. "GSK has one of the strongest sales forces in the industry which is required in order to succeed in this highly competitive market place. Roche and Glaxo were among the first companies to adopt co- promotion in the 1980's with the launch of Zantac in the US. We have demonstrated how we can work together successfully," said William M. Burns, Head of Roche's Pharmaceutical Division. Dr Jean-Pierre Garnier, CEO, GlaxoSmithKline said: "We are really pleased that Roche has chosen GSK as its partner of choice. The addition of ibandronate enhances GSK's late-stage pipeline and we look forward to working with Roche to bring this innovative treatment to women who suffer from osteoporosis." Under the terms of the agreement, Roche and GSK will share the future development and registration costs for the product and Roche will receive certain milestone payments from GSK. Roche will account for all sales of the product. Both companies will share profits. The companies plan to file the first drug applications with the US FDA and in Europe in 2002. Subject to local legal requirements, Roche and GSK plan to co-promote ibandronate in all countries, except Japan.

https://www.chemeurope.com/en/news/6504/gsk-and-roche-announce-collaboration.html